Research paper on the illuminating the evolutionary and epidemic dynamics of XBB variant of G2P-Japan, co-authored by HiLung members, was published in the journal “Nature Communications” on 16 May.
Research paper on the elucidating the evolutionary patterns of Omicron subvariants of G2P-Japan, co-authored by HiLung members, was published in the journal “Nature Communications” on 11 May.
We are joining [2023 RIKEN BDR-CuSTOM Joint Organoid Symposium], KOBE from February 15th -17th.
Selected as Top Drug Discovery Development Solutions Provider in APAC 2022 by Pharma Tech Outlook.
New Year’s Holiday Closing Notice
Research paper on the omicron BA.2.75 variant nicknamed 'Centaurus' of G2P-Japan, co-authored by HiLung members, was published in Cell Host & Microbe on October 9.
We will be exhibiting our company booth at IDWeek 2022 (Washington, D.C. /USA) from 19th to 23th OCTOBER.
Research paper on the omicron variant of G2P-Japan, co-authored by HiLung members, was published in Cell on September 13.
Summer Holiday closing Notice
HiLung participates in LIVe2022 (Nice/France) JUNE 13-14.
CEO Yuki Yamamoto is joining GENProtocol Mixer on 27th June.
We will be exhibiting our company booth at 2022 BIO International Convention (San Diego/USA) from 13th to 16th JUNE.
HiLung and Ube Industries announce to sign a Joint Development Agreement for Co-Development of Novel Selective LPA1 Antagonist HL001 for Pulmonary Fibrosis.
Online Showcase@ San Diego 2022
March 1st. 2022 14:00-17:30pm (PST)
New Year’s Holiday Closing Notice
Changes in Board members.
Dr. Yuki YAMAMOTO was appointed as CEO as of September 10, 2021.
We will exhibit our company’s booth at "Bio Japan/JHVS 2021" from 13th to 15th October. (Pacifico Yokohama)
Co-research paper with Kyoto University and Cellfiber Co., Ltd. was published at "Biomaterials" online.
We have received NEDO Entrepreneurs Program（NEP）Grant in 2021.
We are accelerating the development of drug discovery tools and assay services.
We have received a research grant for “Practical Research Project for Rare/Intractable Diseases” from AMED.
We will promote the development of drugs for pulmonary fibrosis through this program.
We have received a research grant for “The Development of Therapeutic Drugs for the Novel Coronavirus Disease (Covid-19) on Emerging and Re-emerging Infectious Diseases (4th)” from AMED.
We will promote research and development related to COVID-19 by utilizing our cell platform.